These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28760885)

  • 1. The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.
    Royer DJ; Carr MM; Gurung HR; Halford WP; Carr DJJ
    J Immunol; 2017 Sep; 199(5):1898-1911. PubMed ID: 28760885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection.
    Royer DJ; Hendrix JF; Larabee CM; Reagan AM; Sjoelund VH; Robertson DM; Carr DJJ
    Mucosal Immunol; 2019 May; 12(3):827-839. PubMed ID: 30670763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
    J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes Simplex Virus 1 (HSV-1) 0ΔNLS Live-Attenuated Vaccine Protects against Ocular HSV-1 Infection in the Absence of Neutralizing Antibody in HSV-1 gB T Cell Receptor-Specific Transgenic Mice.
    Gmyrek GB; Filiberti A; Montgomery M; Chitrakar A; Royer DJ; Carr DJJ
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0ΔNLS vaccine against ocular HSV-1 challenge.
    Carr DJJ; Berube AN; Filiberti A; Gmyrek GB
    Vaccine; 2021 Apr; 39(18):2526-2536. PubMed ID: 33814229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
    Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC-II but not MHC-I responses are required for vaccine-induced protection against ocular challenge with HSV-1.
    Ghiasi H; Cai S; Nesburn AB; Wechsler SL
    Curr Eye Res; 1997 Nov; 16(11):1152-8. PubMed ID: 9395776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.
    Carr DJJ; Gmyrek GB; Filiberti A; Berube AN; Browne WP; Gudgel BM; Sjoelund VH
    Immunohorizons; 2020 Oct; 4(10):608-626. PubMed ID: 33037098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient mucosal vaccination mediated by the neonatal Fc receptor.
    Ye L; Zeng R; Bai Y; Roopenian DC; Zhu X
    Nat Biotechnol; 2011 Feb; 29(2):158-63. PubMed ID: 21240266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
    Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis.
    Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG
    PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with different HSV-1 glycoproteins induces different patterns of ocular cytokine responses following HSV-1 challenge of vaccinated mice.
    Ghiasi H; Hofman FM; Cai S; Perng GC; Nesburn AB; Wechsler SL
    Vaccine; 1999 Jun; 17(20-21):2576-82. PubMed ID: 10418905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular Immunization of Mice with the Live-Attenuated Herpes Simplex Virus 1 Vaccine Strain VC2 Expressing Equine Herpesvirus 1 (EHV-1) Glycoprotein D Generates Anti-EHV-1 Immune Responses in Mice.
    Liu SA; Stanfield BA; Chouljenko VN; Naidu S; Langohr I; Del Piero F; Ferracone J; Roy AA; Kousoulas KG
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28404844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local expression of tumor necrosis factor alpha and interleukin-2 correlates with protection against corneal scarring after ocular challenge of vaccinated mice with herpes simplex virus type 1.
    Ghiasi H; Wechsler SL; Kaiwar R; Nesburn AB; Hofman FM
    J Virol; 1995 Jan; 69(1):334-40. PubMed ID: 7983727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific and nonspecific immune stimulation of MHC-II-deficient mice results in chronic HSV-1 infection of the trigeminal ganglia following ocular challenge.
    Ghiasi H; Perng GC; Hofman FM; Cai S; Nesburn AB; Wechsler SL
    Virology; 1999 Jun; 258(2):208-16. PubMed ID: 10366558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With γδT Cell Intracorneal Infiltration.
    Nabi R; Lewin AC; Collantes TM; Chouljenko VN; Kousoulas KG
    Front Immunol; 2021; 12():789454. PubMed ID: 34868077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein.
    Ghiasi H; Nesburn AB; Wechsler SL
    Vaccine; 1996 Feb; 14(2):107-12. PubMed ID: 8852405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.